<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076812</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-09-02</org_study_id>
    <nct_id>NCT05076812</nct_id>
  </id_info>
  <brief_title>Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients</brief_title>
  <official_title>Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      case control study to compare level of interleukin 38 in patients with psoriasis and patients&#xD;
      with metabolic syndrome with healthy control subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      this case control study will measure plasma level of interleukin 38 in 4 groups of 24&#xD;
      subject, group one will have psoriatic patients, group 2 will have psoriatic patients with&#xD;
      metabolic syndrome, group three will have patients with metabolic syndrome only, and group 4&#xD;
      will have healthy control subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>measure plasma level of interleukin 38 in all groups</measure>
    <time_frame>through study completion an average of 18 months</time_frame>
    <description>level of interleukin 38 will be measured and compared in all groups to asses the relationship between this interleukin and metabolic syndrome in psoriatic patients</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Group 1 (Psoriasis only)</arm_group_label>
    <description>contains 24 psoriatic patients, Psoriasis Area Severity Index will be measured, also waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile and finally: plasma level of interleukin 38</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Psoriasis and metabolic syndrome)</arm_group_label>
    <description>contains 24 psoriatic patients with metabolic syndrome. Psoriasis Area Severity Index will be measured metabolic syndrome is diagnosed after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (Metabolic syndrome only)</arm_group_label>
    <description>contains 24 patients with metabolic syndrome only. full dermatological examination to exclude psoriasis and other inflammatory skin disorders metabolic syndrome is diagnosed after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 (Healthy Controls)</arm_group_label>
    <description>contains 24 healthy control subjects full dermatological examination to exclude psoriasis and other inflammatory skin disorders metabolic syndrome is excluded after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>measure plasma level of interleukin 38 by ELISA kit</intervention_name>
    <description>draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test</description>
    <arm_group_label>Group 1 (Psoriasis only)</arm_group_label>
    <arm_group_label>Group 2 (Psoriasis and metabolic syndrome)</arm_group_label>
    <arm_group_label>Group 3 (Metabolic syndrome only)</arm_group_label>
    <arm_group_label>Group 4 (Healthy Controls)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        people attending the Dermatology Outpatient Clinics of Sohag University Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  specific to each group&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal. Age &lt;18 years Pregnancy Lactation smoking Infections. Patients with&#xD;
             other inflammatory skin disorders use of antioxidant and anti-inflammatory drugs&#xD;
             patients on treatment for psoriasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yomna a abdellatif, MBBCH</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Yomna A Abdellatif, MBBCH</last_name>
    <phone>01119200320</phone>
    <phone_ext>+2</phone_ext>
    <email>yomna.a.abdellatif@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>wafaa m abdel-magid, asst prof</last_name>
    <phone>0 100 8813349</phone>
    <phone_ext>+2</phone_ext>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Yomna Abdo Abdellatif</investigator_full_name>
    <investigator_title>resident doctor in dermatology venereology and andrology department in sohag university hospital</investigator_title>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>interleukin 38</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

